ArticleJournal of cellular and molecular medicine2025
Ginsenoside Rg5 Improves Radiation-Induced Heart Injury via PPARG/PDK1/AKT1 Pathway.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ginsenoside Rg5 Improves Radiation-Induced Heart Injury via PPARG/PDK1/AKT1 Pathway.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ginsenoside Rg5 (G-Rg5), a rare extract of ginseng, has proven to be valuable for a wide range of clinical applications. However, the role of G-Rg5 in radiation-induced heart injury is currently unclear. This study aims to explore the intervention effect and possible treatment mechanism of G-Rg5 on radiation-induced heart injury. We investigated the impact of G-Rg5 on radiation-induced heart injury through in vivo and in vitro studies. Network pharmacology was employed to explore potential key targets and molecular mechanisms. Various experimental methods were utilised to validate the effects of G-Rg5 on the PPARG/PDK1/AKT1 pathway. G-Rg5 alleviated radiation-induced cardiomyocyte apoptosis and cardiac functional impairment. The expression of peroxisome proliferator activated receptor gamma (PPARG) was upregulated following G-Rg5 treatment, thereby suppressing the transcription of phosphoinositide-dependent protein kinase 1 (PDK1), a predicted target gene regulated by PPARG, to enhance AKT serine/threonine kinase 1 (AKT1) phosphorylation levels. The protective effect of G-Rg5 against radiation-induced heart injury was found to be compromised upon inhibition or knockdown of PPARG. The interaction between PPARG and PDK1 was confirmed by the results of chromatin immunoprecipitation and luciferase reporter assays. G-Rg5, through the upregulation of PPARG expression, induces the transcription of PDK1 and subsequently enhances the phosphorylation levels of AKT1. Ultimately, this process plays a crucial role in mitigating cellular apoptosis and functional decline in radiation-induced heart injury. Therefore, G-Rg5 holds great potential as a therapeutic agent for radiation-induced heart injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.